Bristol Myers Squibb is once again asking the United States Supreme Court to rehear its CAR-T patent dispute against Gilead Sciences. The high court already declined to hear the case, which asks for the reinstatement of a $1.2 billion award to BMS, earlier this month, but the drugmaker is asking again in light of Amgen’s revived Repatha patent case. BMS and Gilead’s CAR-T therapies, Breyanzi and Yescarta, are currently approved to treat certain forms of lymphoma. Breyanzi holds covered or better status for 31% of all insured lives under the pharmacy benefit, and 83% under the medical benefit, compared to Yescarta’s coverage rates of 29% and 86%.
SOURCE: MMIT Analytics, as of 11/30/22